← Back to Search

Atezolizumab for Ovarian Cancer

Phase 2

Waitlist Available

Led By Stephanie Lheureux, M.D.

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back or gotten worse after standard treatment. The new treatment is a combination of atezolizumab and bevacizumab.

Eligible Conditions

Endometrioid Tumor
Ovarian Cancer
Peritoneal Cancer
TP53

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants where increase in circulating deoxyribonucleic acid (ctDNA) level is related to progression

Secondary outcome measures

Disease free survival rate

Number of participants with adverse events

Number of participants with disease free survival with change from detectable to undetectable TP53 ctDNA

+1 more

Side effects data

From 2019 Phase 3 trial • 1225 Patients • NCT02008227

36%

Fatigue

35%

Alopecia

24%

Diarrhoea

23%

Nausea

23%

Decreased appetite

22%

Anaemia

20%

Asthenia

19%

Cough

19%

Dyspnoea

16%

Myalgia

15%

Neutropenia

14%

Constipation

14%

Oedema peripheral

12%

Pyrexia

11%

Neuropathy peripheral

11%

Vomiting

11%

Stomatitis

10%

Arthralgia

Rash

Neutrophil count decreased

Dysgeusia

Paraesthesia

Headache

Pain in extremity

Peripheral sensory neuropathy

Insomnia

Mucosal inflammation

Back pain

Pneumonia

Febrile neutropenia

Abdominal pain

Dry skin

Lacrimation increased

Dizziness

Haemoptysis

Weight decreased

Malaise

Urinary tract infection

Nail disorder

Productive cough

Chest pain

Nasopharyngitis

Musculoskeletal pain

Bronchitis

Pruritus

Upper respiratory tract infection

Alanine aminotransferase increased

Aspartate aminotransferase increased

Influenza like illness

Respiratory tract infection

Musculoskeletal chest pain

Lower respiratory tract infection

Acute kidney injury

Depression

Lung infection

Dehydration

Chronic obstructive pulmonary disease

Atrial fibrillation

Syncope

Pleural effusion

100%

80%

60%

40%

20%

Study treatment Arm

Docetaxel

Atezolizumab

Trial Design

1Treatment groups

Experimental Treatment

Group I: Atezolizumab and BevacizumabExperimental Treatment2 Interventions

A cycle will be every 3 weeks. Atezolizumab will be given intravenously (by vein) at a dose of 1200 mg once every cycle. Bevacizumab will be given intravenously at a dose of 15 mg/kg once every cycle. Up to 17 cycles of study treatment may be given. Participants may be able to receive the study treatment for more than 17 cycles if the participants and the study doctor thinks that they are benefiting.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Atezolizumab

2017

Completed Phase 3

~5860

Bevacizumab

2013

Completed Phase 4

~5280

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,468 Previous Clinical Trials

484,519 Total Patients Enrolled

15 Trials studying Ovarian Cancer

3,483 Patients Enrolled for Ovarian Cancer

Stephanie Lheureux, M.D.Principal InvestigatorPrincess Margaret Cancer Centre

4 Previous Clinical Trials

226 Total Patients Enrolled

1 Trials studying Ovarian Cancer

40 Patients Enrolled for Ovarian Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How is Atezolizumab typically utilized in patient care?

"Atezolizumab is a frequently recommended therapy for people with non-small cell lung carcinoma. It can furthermore be beneficial to those that have experienced recurrence of their platinum-sensitive epithelial ovarian cancer or postoperative, recurrent non-squamous NSCLC."

Answered by AI

How hazardous is Atezolizumab to human health?

"Atezolizumab's safety has been partially corroborated by clinical data, so it is given a score of 2. As this trial is in Phase 2, there are currently no reliable proofs that the drug can be efficacious."

Answered by AI

Are there any unfilled vacancies for participants in this research?

"As per clinicaltrials.gov, this research initiative is currently recruiting participants; it was initially made available on July 16th 2021 and its latest update occurred on October 21st of the same year."

Answered by AI

Has Atezolizumab been the subject of any other medical experiments?

"At the present time, 621 clinical trials are running which focus on Atezolizumab. 142 of these active studies currently lie in Phase 3. While Taibei, Taiwan holds the majority of researchers studying this medication, there exist 31776 locations where similar investigations into Atezolizumab's efficacy and safety are taking place."

Answered by AI

What is the scope of individuals included in this research project?

"Affirmative, the data on clinicaltrials.gov confirms that this medical trial is actively searching for participants. It was first posted to the platform on July 16th 2021 and has been updated as recently as October 21st 2021. The study requires 20 people to be enrolled from 1 site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

2021. "Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04510584.